Rezolute (NASDAQ:RZLT) Shares Down 14.5%
Shares of Rezolute (NASDAQ:RZLT) dropped 14.5% during mid-day trading on Friday . The company traded as low as $0.09 and last traded at $0.10, approximately 206,843 shares traded hands during trading. An increase of 472% from the average daily volume of 36,190 shares. The stock had previously closed at $0.12.
The stock’s fifty day simple moving average is $0.13.
Rezolute (NASDAQ:RZLT) last issued its earnings results on Thursday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter.
Rezolute, Inc, a clinical stage biopharmaceutical company, specializes in the development of drug therapies for the treatment of patients with metabolic and orphan diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema; and RZ602, a product candidate that is in preclinical trial for the treatment of hereditary angioedema.
Featured Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.